CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 301 enrolled
Drug / intervention
Nebivolol +1 moredrug
Likely dose
Amlodipine 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05513937
NCT05513937Phase 4Completed
CompareCT.gov

Open-laBel, Multicenter, multinatiOnal, inTerventional Clinical Trial to Assess effIcacy and Safety of the Extemporaneous Combination of nEbivoLol and amLodipine in Grade 1-2 Hypertensive patIents Versus Each Monotherapy

Menarini International Operations Luxembourg SA·interventional·Posted Aug 24, 2022·Updated Feb 4, 2025

In Brief

A Phase 4 clinical trial evaluating Nebivolol and Amlodipine for Hypertension. Completed, enrolled 301 participants across 1 site.

Detailed Summary

Study to assess the anti-hypertensive efficacy and safety of the extemporaneous combination of Nebivolol 5 mg in combination with Amlodipine 5 mg or AML 10 mg in lowering the sitting diastolic BP after 8 weeks of treatment inpatients with uncontrolled BP previously treated with Nebivolol (NEB) or Amlodipine (5 mg) monotherapies for at least 4 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesBulgaria
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedAug 24, 2022
Enrollment StartMay 12, 2022
Primary CompletionNov 15, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 3.9 years ago

Interventions

Nebivololdrug

Tablets administered orally once daily according instructions provided by Principal Investigator.

Amlodipinedrug

Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.